AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$LQDA

Liquidia GAAP EPS of -$2.64 misses by $3.60, revenue of $225.3M beats by $11.15M (LQDA:NASDAQ)

Liquidia (LQDA) reported Q3 GAAP EPS of -$2.64, missing estimates by $3.60. Revenue was $225.3M, beating by $11.15M. The company recorded a net loss of $236.3M, including a $389.7M litigation settlement charge.

Original reporting
seekingalpha.com
Published Nov 10, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 11:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Liquidia GAAP EPS of -$2.64 misses by $3.60, revenue of $225.3M beats by $11.15M (LQDA:NASDAQ) — source image
Source · seekingalpha.com
Decision brief

The 30-second read

$LQDABearishHigh
01

Why it matters

The earnings miss and large loss are expected to depress the stock in the near term.

02

Market read

Fresh earnings data for a micro‑cap biotech; likely short‑term downside.

03

What to watch

Potential cash infusion from the settlement and any forward guidance were not disclosed.

Relevance 8/10Novelty 8/10Timing: after‑hours release

Background

Liquidia Therapeutics reported its Q3 2026 results, highlighting a significant litigation settlement.

Company-level read

Ticker impact

$LQDABearishHigh confidence
Context

Q3 GAAP EPS of -$2.64 missed expectations and a $389.7M litigation settlement caused a $236.3M net loss.

Expected impact

downward pressure as investors price in the earnings miss and settlement charge

Evidence & confidence

Both EPS and net loss were worse than expected, which typically triggers a sell-off in micro‑cap stocks.

Market effects

Sector

Minimal; impact confined to biotech/life‑science micro‑caps.

Regional

None

Global

Low

Counterpoint

What could challenge this read

If the settlement resolves a major liability, the long‑term outlook could improve despite the short‑term hit.

Key entities

  • Company
    Liquidia Therapeutics

    Biotech firm listed on NASDAQ (LQDA).

Read at source← All news

StoryLiquidia posts strong Q3 sales and adjusted EBITDA growth, but GAAP loss driven by $389.7M settlement charge

Also covered by

4 outlets

Related articles

$LQDAMedAI 8/10

Why is Liquidia stock gaining today?

Liquidia Corporation (LQDA) shares rose 1.4% in pre-market trading after reporting Q3 2026 results. Revenue of $225.3M beat estimates, driven by $222.7M in YUTREPIA sales, up 31% from the prior quarter. A $389.7M litigation charge resulted in a GAAP net loss of $2.64 per share, but operational metrics showed growth, including record patient shipments and an expanding prescriber base. The company's cash position increased to $396.1M.

investing.com
$LQDAMed

Liquidia Reports Strong Third-Quarter YUTREPIA Sales Growth

Liquidia (LQDA) reported Q3 2026 net sales of $222.7M for YUTREPIA, up 31% from Q2, with October patient shipments at a record high. The company settled litigation with United Therapeutics, incurring a $389.7M charge and a Q3 net loss of $236.3M. Non-GAAP adjusted EBITDA was $140.5M, up for the fifth consecutive quarter. Cash reserves were $396.1M at Q3's end. The FDA granted Fast Track designation to YUTREPIA for a new indication, and the company initiated two new studies.

tipranks.com
$LQDAHighAI 8/10

Liquidia Corporation Reports Third Quarter 2026 Financial Results

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of $222.7 million in the third quarter of 2026, up 31% from the second quarter of 2026 · October 2026 total patient shipments reached thei

SEC EDGAR 8-K